Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Odyssey Health, Inc. Forms Community-Based Partnership with David R. Metcalf Foundation for Military Concussion Research

Odyssey Group Intl Inc.

McapMediaWire -- Odyssey Health, Inc. (OTC: ODYY ), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announces a Community-Based Partnership (CBP) with the David R. Metcalf Invisible Wounds Foundation, a non-profit organization that advances brain health care for active duty military and veterans by addressing traumatic brain injury (TBI) and suicide prevention among Naval Special Warfare and special operations forces. Between 2001 and 2021, over 30,000 active-duty personnel and veterans who served in the military after 9/11 died by suicide, compared to the 7,057 service members who died in combat during that same 20-year period. David Metcalf was a Navy SEAL, commissioned naval officer, and physician assistant. Following consecutive deployments and multiple TBIs, David was one of the many warriors who took his own life. Repetitive TBI is linked to Post-Traumatic Stress Disorder (PTSD), Post-Concussion Syndrome (PCS) and mental illness. Each of these conditions increase the rate of suicidal ideation and completion. A Community-Based Partnership (CBP) allows Odyssey Health’s scientific researchers across multiple disciplines to work side-by-side with the Metcalf Foundation’s community – many of whom have lived experience with TBI. The CBP assists in the development of Odyssey Health’s drug for treating TBI, specifically mild TBI (concussion). The CBP will include a needs assessment, clinical trial site planning, research intervention design, implementation, evaluation, and dissemination of community-level interventions. It is the CBP’s intent to enlist the support of the military community connected to The Metcalf Foundation with the research and scientists at Odyssey Health. This partnership will help make sure TBI interventions respond to the military community’s, particularly special operation forces, needs. The CEO of the David R. Metcalf Invisible Wounds Foundation is Shannon Finn Connell, Ph.D. She is a U.S. Navy SEAL parent and serves as an advisor to the Navy SEAL Foundation focused on initiatives for warriors transitioning from military service to civilian life. Shannon is a former executive with SYSCO, Shell Oil, and Procter & Gamble. She obtained her Ph.D. in organizational development, researching design thinking as a problem-solving method in global organizational change initiatives. “Our foundation is active in coordinating research groups, finding funding for care, and bringing awareness to the devastating epidemic of TBI and suicide in our Naval Special Warfare and special operations forces communities. We work with military members, both active and retired, and their families, who face their own challenges as TBI and suicide effects the mental fortitude of loved ones. We are excited by a potential treatment for acute concussion. Highly trained warriors, like David, are medically qualified to take care of themselves and team members in training and combat. The Metcalf Foundation believes the nasal device care and temperature stability of Odyssey Health’s drug will give it a greater chance of success and promote its use in this community of war fighters.” “Odyssey Health recognizes the need to have a partner associated with the US military that can not only give firsthand feedback about the effects of concussion but also help address logistics of treating the condition out in the field. Military medicine has different barriers to care than civilian medicine and we are excited to partner with the Metcalf Foundation to help us navigate and develop the first acute treatment for concussion,” commented Michael Redmond, Chief Executive Officer for Odyssey Health. “I am excited to be working with The Metcalf Foundation and Odyssey Health to develop an acute treatment for brain injury which is absolutely needed for our military men and women. Understanding the environment and logistics to care for our Special Operations Forces will be critical for the clinical success of Odyssey’s treatment. I will be assisting the Metcalf Foundation in establishing community feedback needed from our special forces operators to properly design and implement Odyssey Health’s clinical trials,” commented Tim Szymanski, Vice Admiral (Retired) and former Deputy Commander of the United States Special Operations Command. About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus on life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com We encourage our shareholders to visit our corporate social media accounts for updates: https://twitter.com/OdysseyHealth1 https://www.facebook.com/odysseyhealthinc https://www.linkedin.com/company/odysseyhealthinc https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q About ONP-002 ONP-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, ONP-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that ONP-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, ONP-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. Forward-Looking Statements This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete clinical trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions. Inquiries: Odyssey Health info@odysseyhealthinc.com David R. Metcalf Invisible Wounds Foundation info@davidrmetcalf.org Contact Details Odyssey Health Michael Redmond info@odysseyhealthinc.com

February 07, 2023 08:30 AM Eastern Standard Time

Precigen Is Pioneering a Nonsurgical Treatment for a Debilitating Respiratory Disease; Positive Data Released on Recurrent Respiratory Papillomatosis Showed a 50% Complete Response

Precigen, Inc.

New hope may be on the horizon for sufferers of Recurrent Respiratory Papillomatosis, or RRP, a rare and debilitating disease that typically requires patients to undergo multiple surgeries each year to remove benign tumors called papillomas, that grow in the respiratory tract. Precigen, Inc. (Nasdaq: PGEN ) released complete data at a virtual R&D Day event on January 24, 2023 at 4:30 PM ET from a robust, open label Phase 1 trial of its investigational candidate PRGN-2012, an innovative gene-based immunotherapy designed to inhibit or prevent the growth of the dreaded papillomas in the hopes of reducing the number of surgeries. Clinical data presented showed a strong response in RRP patients with 50% of patients in complete response, requiring no post-treatment surgeries, following PRGN-2012 treatment at Dose Level 2. All complete responders remained surgery-free post-treatment with a minimum 12-months of follow up. PRGN-2012 treatment at Dose Level 2 significantly reduced the need for surgeries in severe, aggressive RRP patients with the median number of surgeries in 12-month period being reduced from 6.5 pre-treatment to 0.5 post-treatment. The data also showed that PRGN-2012 was very well tolerated by patients, with no dose-limiting toxicities or treatment-related adverse events above Grade 2. A Phase 2 trial of PRGN-2012 in RRP is also underway and, depending on the results, it may qualify as a pivotal trial to facilitate the filing of a Biologics License Applications (BLA). It is approximately 85 percent enrolled to date. RRP affects both children and adults. Symptoms include a hoarse voice, difficulty sleeping and swallowing, chronic coughing, and breathing problems. In extreme cases, the disease can be fatal because the papillomas cause severe airway obstruction to the lungs and the lungs become flooded with fluids and infection. In a minority of patients RRP can malignantly transform into cancer. The company estimates indicate there are up to 16,000 active cases of RRP in the US and as many as 75,000 total worldwide, although there are believed to be thousands more undiagnosed cases. No therapeutic treatments are currently approved by the FDA. Company estimates suggest PRGN-2012 could have peak annual US sales of approximately $1 billion if approved. There is a high need for safe and effective therapeutic options for RRP. Currently, the only standard-of-care treatment for RRP is repeat surgeries to maintain voice and respiratory function. The sad reality is that many RRP patients require hundreds of surgeries over their lifetimes. The quality of life and economic burden of recurrent surgeries on patients, their families and physicians is very high. The surgeries are only effective at removing the built-up Human Papillomavirus Virus (HPV)-infected lesions in the respiratory tract, but they do not prevent further buildup. Patients often struggle to maintain consistent employment because of the frequent surgeries all while incurring costly medical bills. Moreover, frequent surgeries for RRP can worsen a patient’s condition overtime by potentially increasing the spread of the HPV virus and the likelihood of serious co-morbidities, including breathing issues and loss of vocal function. PRGN-2012 Seen as Promising, Potentially Less Costly Solution Lacking other treatments to potentially reduce the frequency of surgeries, some physicians have turned to off-label use of drugs approved for other indications, but without proven benefit for RRP patients. One such drug is cidofovir, a broad-spectrum antiviral drug from Gilead (GILD) and Pfizer (PFE) that was originally approved for treating CMV and HIV infection. It is prescribed by some physicians treating RRP, but it can cause liver toxicity and patients typically rebound after withdrawal, making it –at best-- a short-term solution. Another is Avastin® from Roche Holdings (RHHBY), an antiangiogenic drug in wide use as a cancer therapy. Avastin has been shown to temporarily slowdown papilloma growth in some RRP patients. However, it can cause severe side effects and cannot activate specific T cells needed to eliminate HPV infected cells responsible for papilloma growth in RRP. Currently, the most promising solution appears to be Precigen’s PRGN-2012 gene therapy which works by activating anti-HPV T cells to induce immunity against HPV subtypes 6 and 11, which are responsible for RRP. If the on-going Phase 2 trial shows positive results, PRGN-2012 could be on its way to becoming a standard of care for reducing the burden of surgeries, lowering care costs and improving the quality of life of RRP patients. In a study conducted on behalf of Wells Fargo, 10 ear, nose, throat physicians who treat RRP responded very favorably to the use of a drug with a PRGN-2012-target profile of safety and efficacy. Precigen’s clinical-stage pipeline also includes Phase 1 and Phase 2 programs in immuno-oncology and infectious and autoimmune diseases. PRGN-2012 is Precigen’s innovative therapeutic vaccine for RRP patients. Analyst price targets for PGEN as of August 2022 range from $6 to $14, with buy or market outperform ratings issued by Stifel, JMP Securities, Cantor Fitzgerald, and H.C. Wainwright. Click Here for Additional Information About Precigen (PGEN) This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Featured photo By Gorodenkoff on Shutterstock Precigen: Advancing Medicine with Precision ™ Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders,and infectious diseases. Our technologiesenable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Contact Details Steven M. Harasym sharasym@precigen.com Company Website https://precigen.com/

February 07, 2023 08:00 AM Eastern Standard Time

Image

Tulane University Announces First Transformative Agreement with Elsevier

Elsevier

Elsevier, a global leader in research publishing and information analytics, and Tulane University, a leading research institution in the Gulf Coast of the United States, are pleased to announce the institution’s new transformative agreement for reading and publishing. The Transformative Agreement will continue to provide access to the same extensive portfolio of ScienceDirect journals that enhance the learning and research experience for the Tulane community while now also supporting all researchers in publishing their research Open Access at no extra cost to the author. Through this agreement, Tulane faculty, students, and staff will have access to Elsevier's extensive library of scholarly journals and eBooks on ScienceDirect. This will give Tulane researchers the tools they need to stay at the forefront of their fields and make and share essential discoveries. In addition to providing access to these resources, the agreement also includes support for open access publishing, allowing Tulane researchers to share their work more broadly and collaborate with colleagues worldwide. “We are very pleased to have worked in partnership with Elsevier to expand the scope of our agreement to now include Open Access publishing options for our scientific and medical communities,” said Tulane University Interim Dean of Libraries Andy Corrigan. “This new arrangement accomplishes three important goals. It supports public access to grant funded research, addresses cost sustainability within our library budget, and it increases the university’s overall return on investment in supporting the acquisition of high-quality library resources such as important ScienceDirect journals that are relied upon by our students, faculty and researchers.” “Elsevier is committed to supporting Tulane’s open access objectives" said James Tonna, Vice President, Elsevier. "We are thrilled to be able to provide Tulane researchers with the tools they need to make important discoveries and contribute to advancing knowledge." --- About Tulane University Tulane University is a private, independent research university in New Orleans, Louisiana. Founded in 1834, Tulane is one of the oldest and most prestigious universities in the southern United States, with a strong tradition of research and teaching in the sciences, engineering, business, law, and the liberal arts. About Elsevier As a global leader in information and analytics, Elsevier helps researchers and healthcare professionals advance science and improve health outcomes for the benefit of society. We do this by facilitating insights and critical decision-making for customers across the global research and health ecosystems. In everything we publish, we uphold the highest standards of quality and integrity. We bring that same rigor to our information analytics solutions for researchers, health professionals, institutions, and funders. Elsevier employs 8,100 people worldwide. We have supported the work of our research and health partners for more than 140 years. Growing from our roots in publishing, we offer knowledge and valuable analytics that help our users make breakthroughs and drive societal progress. Digital solutions such as ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath support strategic research management, R&D performance, clinical decision support and health education. Researchers and healthcare professionals rely on our 2,500+ digitized journals, including “ The Lancet ” and “ Cell ”; our 40,000 e-Book titles; and our iconic reference works, such as “Gray’s Anatomy.” With the Elsevier Foundation and our external Inclusion & Diversity Advisory Board, we work in partnership with diverse stakeholders to advance inclusion and diversity in science, research and healthcare in developing countries and around the world. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. www.elsevier.com Contact Details Andrew Davis Andrew.davis@elsevier.com Company Website https://www.elsevier.com/

February 07, 2023 08:00 AM Eastern Standard Time

Unicycive: This Biotech Company Receives Promising Results From New Trial

Unicycive Therapeutics, Inc.

By Johnny Rice, Benzinga Unicycive Therapeutics Inc. (NASDAQ: UNCY) is a biotechnology company developing drug candidates currently focused on kidney disease. The innovative treatments may have vast potential outside of the specifics of kidney disease as well. Currently, the company has two treatments in development: Renazorb, for treatment of hyperphosphatemia in patients with chronic kidney disease, and UNI-494, for treatment of acute kidney injury. The latter recently passed through a new round of preclinical trials. The results were described as “very encouraging” by a leading expert in the field of AKI (acute kidney injury) research. Learn more here: Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells Watch the video here: This article was originally published on Benzinga here. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

February 06, 2023 09:59 AM Eastern Standard Time

Video

Kane Biotech’s Coactiv+™ Technology Could Address a Pricey and Painful Problem: Lack of Healing in Chronic Wounds Due to Microbial Biofilm Formation

Kane Biotech Inc.

By Richard Dal Monte Chronic wounds are a persistent and pricey problem for patients and health care systems around the world. Defined as “wounds that fail to proceed through the normal phases of wound healing in an orderly and timely manner,” chronic wounds range from severe burns to bedsores to diabetic ulcers. Whatever the cause, they all carry costs in medical care as well as pain and decreased quality of life, and many can be attributed to something you may have never heard of: biofilms. “Biofilms are formed when bacteria and/or fungi adhere to surfaces and excrete a glue-like substance that acts as an anchor and provides protection from the environment,” making “bacteria up to 1,000 times more resistant to antibiotics, antimicrobial agents, disinfectants and the host immune system,” according to Kane Biotech Inc. (TSX-V: KNE | OTCQB: KNBIF). The Canadian company’s latest product, coactiv+ ™ Antimicrobial Hydrogel, is designed to address biofilms and the problems they cause in chronic wounds — and at a price that will allow it to be covered by Medicare in the U.S. as well as insurers around the globe, a crucial distinction for a premium product. “The things we normally used very effectively to kill bacteria — like antibiotics, our own immune cells, our antibodies — they frequently are ineffective in killing these biofilm bacteria,” explains Dr. Gregory Schultz, a University of Florida professor emeritus and Kane Biotech’s chief scientific officer. Schultz says Kane’s coactiv+ ™ technology not only addresses biofilm-impaired healing, but it also contains an antimicrobial molecule that allows it to be effective in healing chronic wounds. And he notes the gel could be applied by a doctor, nurse or even patients themselves. Biofilms are a serious problem in the majority of chronic wounds “It’s a great technology. It’s important technology,” says Marc Edwards, Kane Biotech’s CEO, noting biofilms are one of the largest unresolved problems associated with chronic wounds. Studies have shown a prevalence of biofilms in more than 78 per cent of chronic wounds and the U.S. Centers for Disease Control and Prevention have identified resistant bacteria, to which biofilms are a major contributor, as a serious burden to health care systems. Edwards says that Kane has filed a 510(k) application with the U.S. Food and Drug Administration —a submission that demonstrates that the medical device (in this case, Kane’s coactiv+ ™ Antimicrobial Hydrogel) “is as safe and effective, that is, substantially equivalent, to a legally marketed device” — so it can bring the product to market. The review process is well underway, and approval is expected by the second quarters of 2023, with a commercial launch planned for the third quarter. Edwards is optimistic about the product’s prospects because of the cost of chronic wounds to health care systems. For instance, “Studies of [U.S.] Medicare data estimate the cost to treat these wounds at between US$28 billion and US$96 billion.” And according to a 2022 report by Grand View Research Inc., the global wound care market is estimated to grow to US$29.6 billion by 2030. In addition, Hydrogels are used daily by wound care practitioners, Edwards says, representing a $150-$200 million market in the U.S. that is ripe for a clearly differentiated, premium product such as coactiv+ ™. The Kane product is distinct both in its ability to inhibit biofilm formation as well as in its thermo-reversible formulation, which means it gels at warmer temperatures and liquifies at cooler temperatures; thus, it can be cooled to be poured on to burn wound — it will gel when in contact with body heat — and rinsed off easily with cold water. Kane Biotech will soon be in the South American market thanks to partnership Already, Kane Biotech has taken steps to access the market for wound care and hydrogels by signing a distribution agreement earlier this year with Salud Pharma S.A., which will, once the product has received FDA approval, commercialize coactiv+ ™ (as well as Kane’s DermaKB ™ scalp care products) throughout Colombia, Panama and Costa Rica. Photo: The DermaKB ™ product line up. In addition to wound and surgical care, Kane Biotech — which has been granted approximately US$3.1 million in research funding from the U.S. Department of Defense for DispersinB®, the company’s other patented antibiofilm technology — is also focused on dermatology and animal health. The company has also developed DermaKB ™ scalp detoxifiers and shampoos designed to break down biofilm. Containing its proprietary coactiv+ ™ technology, these lineups of products are proven to help with scalp conditions such as dandruff and seborrheic dermatitis. Edwards notes Kane’s anti-biofilm technology serves as a platform on which to build a variety of products. “Besides our focus in R&D, we are also a product development firm. We’re looking to build multiple royalty streams,” Edwards says. “We’re really at an inflection point. With the launch of our coactiv+ ™ Antimicrobial Wound Gel and developing product pipeline, we aim to tap into a multi-million-dollar market that is ripe for the picking. Since this market is still relatively untouched, we believe that there is a real opportunity to own it.” Learn more about Kane Biotech Inc. on its website as well as: Facebook Instagram Twitter LinkedIn YouTube This article was originally published on Benzinga here. Kane Biotech is a biotechnology company engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (80 patents and patents pending, trade secrets and trademarks) and products developed by the Company's own biofilm research expertise and acquired from leading research institutions. StrixNBTM, DispersinB®, Aledex™, bluestem™, bluestem®, silkstem™, goldstem™, coactiv+™, coactiv+®, DermaKB™ and DermaKB Biofilm™ are trademarks of Kane Biotech Inc. The Company is listed on the TSX Venture Exchange under the symbol "KNE" and on the OTCQB Venture Market under the symbol “KNBIF” This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, but are not limited to, the availability of funds and resources to pursue R&D activities, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in its specific industry, and uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's ongoing filings which are available on SEDAR for additional information on risks and uncertainties relating to forward-looking statements. Investors are cautioned not to rely on these forward-looking statements nor does the Company undertake to update or revise any these forward-looking statements contained herein. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details Nicole Sendey nsendey@kanebiotech.com

February 06, 2023 09:35 AM Eastern Standard Time

Image

Robert Bache Joins AmeriLife as Vice President of Health

AmeriLife

AmeriLife Group, LLC (“AmeriLife”), a national leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions, today announced the appointment of Robert Bache to Vice President, Health. “As AmeriLife’s Health Distribution continues to grow by leaps and bounds, it’s important that we surround our partners with the expertise and leadership to help accelerate their business,” said Scotty Elliott, Chief Distribution Officer for AmeriLife’s Health Distribution. “Having Bobby join our leadership ranks is nothing short of a coup for AmeriLife, and I’m thrilled to welcome him to our team.” A Medicare expert known throughout the industry as “Medicare Bob,” Bache has enjoyed a nearly 20-year career as an entrepreneur, author, sales strategist, industry influencer and business leader. He spent more than three years at TRANZACT as a top Medicare Supplement insurance producer before founding Senior Healthcare Direct in 2012. Under Bache's leadership, Senior Healthcare Direct has grown into a leading independent insurance broker helping thousands of beneficiaries across the country navigate, compare and enroll in the right Medicare plan options for them. In his new role, Bache will oversee a portfolio of firms within AmeriLife’s Health Distribution, helping to fortify their operations and optimize their synergies with AmeriLife. Bache will also support carrier relations, training and business development efforts for AmeriLife. As a result of Bache’s transition, David Minaya, Senior Healthcare Direct’s vice president of sales, will assume day-to-day management of the agency, reporting to AmeriLife’s President of Direct-to-Consumer, Jim Palmer. “When I joined the AmeriLife family with Senior Healthcare Direct in 2020, it was due in large part to the incredible resources and partners I would gain to help grow my business. Now, I get to help other entrepreneurs and business owners – just like myself – grow theirs, and I couldn’t be more excited for the opportunity,” said Bache. “I’m especially proud for David, and I know he, Christina Ragone [SVP of Operations], and the incredible sales, marketing and support teams will continue to flourish under Jim’s leadership.” ### About AmeriLife AmeriLife’s strength is its mission: to provide insurance and retirement solutions to help people live longer, healthier lives. In doing so, AmeriLife has become recognized as the leader in developing, marketing, and distributing life and health insurance, annuities and retirement planning solutions to enhance the lives of pre-retirees and retirees across the United States. For more than 50 years, AmeriLife has partnered with top insurance carriers to provide value and quality to customers served through a distribution network of over 300,000 insurance agents and advisors and more than 100 marketing organizations and insurance agency locations nationwide. For more information, visit AmeriLife.com, and follow AmeriLife on Facebook and LinkedIn. Contact Details Media Jeff Maldonado +1 321-297-1112 jmaldonado@amerilife.com Partnership Inquiries Patrick Nichols +1 727-726-0726 pnichols@amerilife.com Company Website https://amerilife.com/

February 06, 2023 09:00 AM Eastern Standard Time

News Release

Irwin Naturals acquires Braxia Scientific to expand mental health treatment and R&D

Irwin Naturals Inc.

Irwin Naturals President Adam Berk joined Proactive's Natalie Stoberman with details of the company's acquisition of Braxia Scientific. Berk said the strategic transaction assembles an experienced management and scientific team world-renowned in mental health treatment, research and development. The combination establishes a wider footprint of 22 specialized mental health clinics across North America, enhanced by a telehealth platform expected to extend access to critical treatments for millions of people across multiple states in the US. The newly-combined network of clinics creates a leading international mental health research platform for in-human clinical development of novel therapeutics, Berk added. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

February 06, 2023 07:03 AM Eastern Standard Time

Video

Kadimastem Awarded Patent in Australia for its AstroRx® Technology for the Treatment of ALS and Drug Screening

Kadimastem Ltd.

Kadimastem Ltd. (TASE: KDST), a clinical stage cell therapy company developing a treatment for ALS, and developing a potential cure for diabetes, has received a patent from the Australian Patent Office for production technology of AstroRx ® containing healthy functioning astrocytes for the treatment of ALS and drug screening. This patent accompanies the company's patents for the product in the US, Europe, Japan, and Israel, and is significant to have been granted before the planned phase IIa clinical trial in the US scheduled for the coming year. The patent protects the manufacturing technology of the company's leading product, AstroRx®, for the use and treatment of ALS (Amyotrophic Lateral Sclerosis). In addition, the patent protects the use of the company's platform cell-based drug screening technology to discover compounds with therapeutic potential. AstroRx® contains astrocytes, the supporting cells of the central nervous system (brain and spinal cord) whose activity is impaired in many neurological diseases such as ALS. In ALS patients, the ability of astrocytes to maintain a normal survival environment that supports the motor neurons is impaired and as a result there is massive cell loss of the motor neurons, which are responsible for the movement of the voluntary muscles. The company's assumption is that the injection of healthy, functioning astrocytes into the spinal cord fluid of ALS patients in a standard lumbar puncture procedure is expected to compensate for the dysfunction of the diseased astrocytes and support the survival of the suffering motor neurons, thereby slowing the progression of the disease. Unlike small chemical drugs that usually work with a single mechanism of action, the astrocytes operate with several different mechanisms of action at the same time, each of which individually may protect the motor neurons that are affected by the disease. Kadimastem completed a clinical trial (Phase I/IIa), in which the cells were injected into the spinal cord fluid using a standard lumbar puncture procedure in 10 ALS patients. The results of the trial demonstrated a high safety profile, as well as a clinically meaningful effect maintained over the first 3 months period after treatment, as measured by the pre vs post slope change of a clinical score known as ALS Functional Rating Score (ALSFRS-R) Asaf Shiloni, CEO of Kadimastem, commented: "The patent granted in Australia, which joins the patent we received a few months ago in the U.S., continues to strengthen our patent portfolio in the field of treatment for ALS and other neuro-degenerative diseases. This is a testimony and recognition of the innovation of the science developed at Kadimastem and we are working intensively to complete the filing of an IND submission in anticipation to begin clinical trials in the U.S.". Prof. Michel Revel, Kadimastem's Chief Scientist, said: "The ALS program continues to move forward as the company's patent technology continues to strengthen. The company's vision of providing treatment to ALS patients continues to advance, and I am confident that the science developed in the company will greatly help patients in the future." In Australia there are currently about 2,000 ALS patients, with about 730 [1] ALS patients diagnosed each year. About Kadimastem Kadimastem Ltd. is a clinical stage cell therapy company, developing and manufacturing "off-the-shelf", allogeneic, proprietary cell products based on its technology platform for the expansion and differentiation of Human Embryonic Stem Cells (hESCs) into functional cells. AstroRx®, the company's lead product, is an astrocyte based cell therapy in clinical development for the treatment for ALS. IsletRx is the company's second product in development. IsletRx is comprised of functional, insulin producing, pancreatic islet cells intended to treat and cure patients with insulin-dependent diabetes. Kadimastem was founded by Professor Michel Revel, CSO of the company and Professor Emeritus of Molecular Genetics at the Weizmann Institute of Science. Professor Revel received the Israel Prize for the invention and development of Rebif®, a multiple sclerosis blockbuster drug sold worldwide. Kadimastem is traded on the Tel Aviv Stock Exchange (TASE: KDST). Forward Looking Statement This document may include forward-looking information as defined in the Securities Law, 5728 – 1968. Forward-looking information is uncertain and mostly is not under the Company's control and the realization or non-realization of forward-looking information will be affected, among other things, by the risk factors characterizing the Company's activity, as well as developments in the general environment and external factors affecting the Company's activity. The Company's results and achievements in the future may differ materially from any presented herein and the Company makes no undertaking to update or revise such projection or estimate and does not undertake to update this document. This document does not constitute a proposal to purchase the Company's securities or an invitation to receive such offers. Investment in securities in general and in the Company in particular bears risks. One should consider that past performance does not necessarily indicate performance in the future. Company Contacts: Asaf Shiloni CEO INFO@kadimastem.com For more information and/or a meeting with the company's management: Lior Gottlieb, lior@gotlive-ir.co.il, 050-9200194 [1] https://medicalrepublic.com.au/unravelling-the-complexities-of-als/57092 Contact Details Kadimastem Ltd. Asaf Shiloni INFO@kadimastem.com Company Website https://www.kadimastem.com/

February 06, 2023 07:00 AM Eastern Standard Time

Image

News Release

Avicanna says 2022 was transformational despite challenging cannabis market

Avicanna Inc

Avicanna Inc CEO Aras Azadian joined Proactive's Natalie Stoberman with the company's Year in Review including milestones reached in 2022. Azadian said 2022 was challenging for both the biopharmaceutical and cannabis industries. Despite the challenges, Azadian said it was transformational year for Avicanna as it remained focused and deliver on its business plan. Avicanna's aim in 2022 was to commercialize and advance the intellectual property portfolio across its four business units: Active Pharmaceutical Ingredients, Cosmetics, Medical, and Pharmaceutical, which contributed to successful exports to 18 international markets. Contact Details Proactive USA +1 347-449-0879 na-editorial@proactiveinvestors.com

February 03, 2023 12:02 PM Eastern Standard Time

Video

1 ... 166 167 168 169 170 ... 310

Back